Amgen Inc (AMGN)
Health Care ยท Biological Products, (No Diagnostic Substances)
Amgen Inc (AMGN) is listed on Nasdaq, where its shares have traded since June 17, 1983. SentiSense covers Amgen Inc in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances). Robert Bradway is its chief executive officer. The company reports 31,500 employees, and its corporate website is www.amgen.com.
About Amgen Inc
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Latest reported results
Amgen Inc. reported revenue of $10.05 billion for Q2 FY2026, up 9.7% from the same period a year earlier.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 3,124 institutions reported holding AMGN, with 441.6 million shares worth $159.8 billion in aggregate. The largest reported holders were Vanguard, BlackRock and Capital Group. Of the 5 largest reported holders, 4 added shares and 1 reduced its position during the quarter.
More on AMGN
- AMGN sentiment: whether news and social coverage of Amgen Inc leans bullish or bearish, and the stories driving it.
- AMGN ownership: all 3,124 reporting institutions, plus insider and congressional trades.
- AMGN financials: revenue, net income, operating margin and free cash flow through Q2 FY2026.
Frequently asked questions
What does Amgen Inc do?
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases.
What sector is AMGN in?
SentiSense classifies Amgen Inc in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances).
Where does AMGN stock trade?
Amgen Inc (AMGN) is listed on Nasdaq, where its shares have traded since June 17, 1983.
Who is the CEO of Amgen Inc?
Robert Bradway is the chief executive officer of Amgen Inc.